Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Mizuho

Mizuho began coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report released on Friday morning, Marketbeat reports. The brokerage issued an outperform rating and a $8.00 target price on the stock.

Several other brokerages have also recently commented on ZNTL. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Guggenheim lifted their price objective on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $6.14.

Zentalis Pharmaceuticals Trading Up 11.8%

Shares of NASDAQ ZNTL opened at $5.11 on Friday. Zentalis Pharmaceuticals has a 1 year low of $1.21 and a 1 year high of $6.95. The firm’s 50-day moving average is $4.10 and its 200-day moving average is $3.35. The firm has a market capitalization of $363.78 million, a PE ratio of -2.95 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). As a group, equities research analysts anticipate that Zentalis Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently bought and sold shares of ZNTL. JPMorgan Chase & Co. raised its position in shares of Zentalis Pharmaceuticals by 31.4% during the third quarter. JPMorgan Chase & Co. now owns 723,075 shares of the company’s stock worth $1,092,000 after purchasing an additional 172,628 shares during the period. Anfield Capital Management LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 239.9% in the fourth quarter. Anfield Capital Management LLC now owns 242,605 shares of the company’s stock valued at $328,000 after buying an additional 171,228 shares during the period. 5AM Venture Management LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 705.7% in the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after buying an additional 3,457,913 shares during the period. Ishara Investments LP bought a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth $1,782,000. Finally, CTC Alternative Strategies Ltd. bought a new stake in shares of Zentalis Pharmaceuticals during the first quarter worth $29,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.